Come up with a name for your new list and we'll add to it:
Phrixus Pharmaceuticals raised a round of funding on May 21, 2012. Investors include
National Institutes of Health.
Phrixus Pharmaceuticals is developing Carmeseal (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure. Carmeseal has been shown to improve the efficiency of dam…